Navigation Links
Roche Announces Significant Price Reduction of Two ACCU-CHEK(R) Glucose Monitoring Kits to Help Customers With Diabetes During These Difficult Economic Times
Date:2/6/2009

INDIANAPOLIS, Feb. 6 /PRNewswire/ -- Roche announced today that people with diabetes will see a significant price reduction on the price of both the ACCU-CHEK(R) Aviva and ACCU-CHEK(R) Compact Plus Meter Care Kits, effective immediately.

"We are pleased to be able to provide our customers with diabetes two of the leading blood glucose meters on the market at a significantly reduced price," said Roche Vice President of Marketing Dan Kane. "In today's economic environment, we know it's becoming considerably harder for people to make ends meet. Yet it is so important to continue to effectively manage health issues like diabetes by monitoring blood glucose."

Effective immediately, customers will see an everyday shelf price of about $20 for each of the two ACCU-CHEK(R) blood glucose meter care kits wherever ACCU-CHEK(R) products are sold.

Kane added, "We're all feeling the pinch of these current economic times, but there are just some things we shouldn't skimp on-our health is one of those things. By offering people with diabetes new and innovative technology at affordable prices, we hope to encourage them to begin and continue to effectively manage their disease and achieve positive outcomes."

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management-from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.

For more information, please visit www.accu-chek.com.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's largest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Roche Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in vitro diagnostics and drugs for cancer and transplantation as well as a market leader in virology. It is also active in other major therapeutic areas, such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners-including majority ownership interests in Genentech and Chugai-and has invested over 8 billion Swiss francs in R&D in 2007. Worldwide, Roche employs about 79,000 people. Additional information is available on the Internet at www.roche-diagnostics.us.

    For further information, please contact:
    Julie Vincent
    Public Relations Manager
    ACCU-CHEK(R) Brand
    julie.vincent@roche.com
    317-521-1910

'/>"/>
SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rochester Medical Reports First Quarter Results
2. Rochester study raises new questions about controversial plastics chemical
3. University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing
4. Rochester Medical Announces First Quarter 2009 Earnings Conference Call February 2, 2009
5. Rochester Medical Announces Settlement With TYCO Healthcare Group, L.P., Now Operating as Covidien Ltd.
6. Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012
7. Roche Offers Fun Experience with ACCU-CHEK(R) Aviva Through New Rock My Meter Website
8. Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test
9. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
10. Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care
11. New Roche Dual Target HIV-1 Test Approved for Use in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University ... it produces the same kind of electrical energy that the body uses. , ... moving electrons. This flow of electrons out of the battery is generated by moving ...
(Date:7/24/2017)... ... 24, 2017 , ... Cosmetic Town, an online plastic surgery information community, announces ... on a daily basis. , The new video series will feature board-certified doctors ... their practices. , When asked about the new video series, the senior editor ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... in scholarship awards to be awarded annually to and divided between two full-time ... in bringing awareness to Amazonian plant medicine. To apply for the scholarship, students ...
(Date:7/24/2017)... ... 2017 , ... The Topricin Companies, formerly Topical Biomedics, is ... natural, after-burn skin care product, Topricin After Burn Cream. , Overexposure ... conditions, including cancer. In the short term, overexposure to sun, wind and ...
(Date:7/24/2017)... ... , ... Anyone who uses scales know they have limits; a small kitchen ... same scale to dispense medication. The first example is an issue of capacity, while ... is important to have the right balance for the process. METTLER TOLEDO’s new white ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
Breaking Medicine Technology: